KDR and small cell lung carcinoma: Second, for SCLC patients with LM, therapeutic efficacy may be unfavorable due to dysfunction and insufficiency of effector T cells in the TME; therefore, treatments that improve the immunosuppressive microenvironment, such as VEGFR blockade, should be considered to enhance the response to immunotherapy by modulating the TME.